InsidersTradesSigma
Track the 지에프씨생명과학 stock price and the full insider trade history of the company, a listed equity based in South Korea. Shares trade on the KR market, under the oversight of DART (FSS). Operating in the Health Care sector, 지에프씨생명과학 has published 6 insider filings. Market capitalisation: €29.8bn. The latest transaction was reported on 10 April 2026 (Purchase). Among the most active insiders: 강희철. Every trade is free.
6
Insider Decl.
n/a
Thresholds
€210,842
6 ops.
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,516 of 29,063 companies
35.4
score / 100
Value26
Quality45
FCF yld-20%
Earn yld1.8%
EV/EBITDA18.5x
ROE4.1%
Gross mgn48%
Net mgn3.1%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 10 April 2026
Declarations6 total
6 of 6 declarations
Acerca de 지에프씨생명과학
지에프씨생명과학 es una empresa que opera en el sector de la salud y farmacéutico, cotizada en el mercado XKRX. Se enfoca en desarrollar soluciones innovadoras para el cuidado de la salud.